NewYork-Presbyterian, in partnership with Weill Cornell Medicine and Columbia University, remains at the forefront of clinical research related to pulmonary hypertension. Our experts are responsible for some of the earliest genetic studies in the field along with ground-breaking clinical trials evaluating new medical treatments—including the first drug approved for pulmonary hypertension (intravenous epoprostenol) in 1995.
Heart Failure Research Institute
Advancing the understanding, prevention, and treatment of heart failure through research
Pulmonary Hypertension
Advancing Precision Medicine
Dr. Evelyn Horn and colleagues are recognized as leaders for their hemodynamic approach to complex pulmonary hypertension and right heart dysfunction, be it Group 1-5 or mixed group taxonomies. Our team has been part of the 7 center NIH study (PVDOMICS), applying extensive clinical phenotyping inclusive of multidimensional imaging, cutting-edge physiological testing in the cath lab, exercise testing, and precision medicine in the assessment of pulmonary vascular disease and right heart failure. We have the benefit of close collaboration with colleagues at the PVDOMICS sites, our expert CV imagers, and the Englander Institute for Precision Medicine. Explore our work below.
Our Research
Study highlights
Heterogeneity in Group 1 PH
Increasingly, Group 1 PAH with distinct CV and pulmonary phenotypes have been appreciated in current cohorts distinct from younger historic PAH. Current algorithms recommend more cautious use of PAH therapies in these groups due to potential worsening of LA hypertension in CV patients and worsened V/Q mismatch in chronic lung patients. In PVDOMICS we assessed them as Mixed Groups 1,2 and 1,3 with appropriate physiology beyond mere co-morbidities.
Aging and the cardiopulmonary system in pulmonary Vascular disease
Overlapping with above, markers of senescence are more likely to be associated with cardiovascular and pulmonary cohorts and as the world of senescence biology expands, likely to have meaningful expression here.
Metabolomics of RV dysfunction
RVF has a different metabolic expression and a better understanding of the peripheral expression of such vs gradients across the pulmonary circulation.
Hemodynamic monitoring in Cpc-PH with cardiomems
Increasingly our PH-HFpEF are getting cardiomems. As abnormal pulmonary capacitance is the pulsatile load contributing to RV failure and is dictated by SV/PA PP, aside from monitoring filling pressure trends, we can analyze effective pulmonary capacitance.
Atrial remodeling
Most of the focus re cardiac remodeling has been at the ventricular level but evidence suggests that RA for pulmonary hypertension and LA for PH-HFpEF & VHD, particularly with Cpc-PH may offer some of the hidden clue(s).
CTD and its expression in heart and lungs
What are we missing when we don’t look: 1) Paucity immune pathology ; 2) anti endothelial antibodies with similarities to antibody mediated rejection; 3) possible presence of complement mediated, interferon related pathways. Additionally, can we learn anything with use of microvascular assessment
Recent publications
High Pulmonary Hypertension Risk by Echocardiogram Shortens Survival in Polycythemia Vera.
Gazda AJ, Pan D, Erdos K, Abu-Zeinah G, Racanelli A, Horn EM, Scandura JM. Blood Adv. 2024 Dec 18:bloodadvances.2024013970. doi: 10.1182/bloodadvances.2024013970. Online ahead of print. PMID: 39693509.
Mukherjee M, Mathai SC, Jellis C, Freed BH, Yanek LR, Agoglia H, Chiu C, Jani VP, Simpson CE, Brittain EL, Tang WHW, Park MM, Hemnes AR, Rosenzweig EB, Rischard FP, Frantz RP, Hassoun PM, Beck G, Hill NS, Erzurum S, Thomas JD, Kwon D, Leopold JA, Horn EM, Kim J; PVDOMICS Study Group. Circ Cardiovasc Imaging. 2024 Oct;17(10):e017074. doi: 10.1161/circimaging.124.017074. Epub 2024 Oct 15. PMID: 39691460.
Alterations in Mitochondrial Function in Pulmonary Vascular Diseases.
Farha S, Asosingh K, Hassoun PM, Barnard J, Comhair S, Reichard A, Wanner N, Radeva M, Aldred MA, Beck GJ, Berman-Rosenzweig E, Borlaug BA, Finet JE, Frantz RP, Grunig G, Hemnes AR, Hill N, Horn EM, Jellis C, Leopold JA, Mehra R, Park MM, Rischard FP, Tang WHW, Erzurum SC; PVDOMICS Study Group. Antioxid Redox Signal. 2024 Dec 10. doi: 10.1089/ars.2024.0557. Online ahead of print. PMID: 39655485.
Frantz RP, Desai SS, Ewald G, Franco V, Hage A, Horn EM, LaRue SJ, Mathier MA, Mandras S, Park MH, Ravichandran AK, Schilling JD, Wang IW, Zolty R, Rendon GG, Rocco MA, Selej M, Zhao C, Rame JE. Pulm Circ. 2024 Dec 4;14(4):e12446. doi: 10.1002/pul2.12446. eCollection 2024 Oct. PMID: 39635465.
Shelburne NJ, Nian H, Beck GJ, Casanova NG, Desai AA, DuBrock HM, Erzurum S, Frantz RP, Hassoun PM, Hill NS, Horn EM, Jacob MS, Jellis CL, Joseloff E, Kwon DH, Brett Larive A, Leopold JA, Park MM, Rischard FP, Rosenzweig EB, Vanderpool RR, Yu C, Hemnes AR; Redefining Pulmonary Hypertension Through Pulmonary Vascular Disease Phenomics Study Group. CHEST Pulm. 2024 Sep;2(3):100046. doi: 10.1016/j.chpulm.2024.100046. Epub 2024 Mar 11.PMID: 39524046.
Reddy YNV, Frantz RP, Hassoun PM, Hemnes AR, Horn E, Leopold JA, Rischard F, Rosenzweig EB, Hill NS, Erzurum SC, Beck GJ, Finet JE, Jellis CL, Mathai SC, Tang WHW, Borlaug BA. J Am Coll Cardiol. 2024 Nov 26;84(22):2196-2210. doi: 10.1016/j.jacc.2024.08.061. Epub 2024 Oct 23. PMID: 39453363.
Villar-Calle P, Kochav JD, Vadaketh K, Chiu C, Tak K, Agoglia H, Liberman N, Nguyen KL, Vizcarra-Tellez A, Wu A, RoyChoudhury A, Khalique OK, Judd RM, Kim RJ, Shah DJ, Heitner JF, Farzaneh-Far A, Shenoy C, Owyang CG, Mukherjee M, Horn EM, Weinsaft JW, Kim J. Circ Cardiovasc Imaging. 2024 Aug;17(8):e016852. doi: 10.1161/CIRCIMAGING.124.016852. Epub 2024 Aug 20. PMID: 39163376.
Reddy YNV, Dubrock H, Hassoun PM, Hemnes A, Horn E, Leopold JA, Rischard F, Rosenzweig EB, Hill NS, Erzurum SC, Beck GJ, Mathai SC, Mukherjee M, Tang WHW, Borlaug BA, Frantz RP; and the PVDOMICS Study Group. Eur J Heart Fail. 2024 Nov;26(11):2323-2336. doi: 10.1002/ejhf.3396. Epub 2024 Jul 26. PMID: 39058211.
Pulmonary hypertension across the spectrum of left heart and lung disease.
Borlaug BA, Larive B, Frantz RP, Hassoun P, Hemnes A, Horn E, Leopold J, Rischard F, Berman-Rosenzweig E, Beck G, Erzurum S, Farha S, Finet JE, Highland KB, Jacob M, Jellis C, Mehra R, Renapurkar R, Singh H, Tang WHW, Vanderpool R, Wilcox J, Yu S, Hill N. Eur J Heart Fail. 2024 Jul;26(7):1642-1651. doi: 10.1002/ejhf.3302. Epub 2024 Jun 4. PMID: 38837273.
Vohra AS, Olonoff DA, Ip A, Kirtane AJ, Steinberg Z, Horn E, Krishnan U, Reisman M, Bergman G, Wong SC, Feldman DN, Kim LK, Singh HS. Pulm Circ. 2024 May 9;14(2):e12374. doi: 10.1002/pul2.12374. eCollection 2024 Apr. PMID: 38736894.
Lowery MM, Hill NS, Wang L, Rosenzweig EB, Bhat A, Erzurum S, Finet JE, Jellis CL, Kaur S, Kwon DH, Nawabit R, Radeva M, Beck GJ, Frantz RP, Hassoun PM, Hemnes AR, Horn EM, Leopold JA, Rischard FP, Mehra R; Pulmonary Vascular Disease Phenomics (PVDOMICS) Study Group. J Am Coll Cardiol. 2023 Nov 21;82(21):1989-2005. doi: 10.1016/j.jacc.2023.09.806. PMID: 37968017.
Simpson CE, Ambade AS, Harlan R, Roux A, Aja S, Graham D, Shah AA, Hummers LK, Hemnes AR, Leopold JA, Horn EM, Berman-Rosenzweig ES, Grunig G, Aldred MA, Barnard J, Comhair SAA, Tang WHW, Griffiths M, Rischard F, Frantz RP, Erzurum SC, Beck GJ, Hill NS, Mathai SC, Hassoun PM, Damico RL; the PVDOMICS Study Group. Am J Physiol Lung Cell Mol Physiol. 2023 Nov 1;325(5):L617-L627. doi: 10.1152/ajplung.00177.2023. Epub 2023 Oct 3. PMID: 37786941.
Rischard FP, Bernardo RJ, Vanderpool RR, Kwon DH, Acharya T, Park MM, Katrynuik A, Insel M, Kubba S, Badagliacca R, Larive AB, Naeije R, Garcia JGN, Beck GJ, Erzurum SC, Frantz RP, Hassoun PM, Hemnes AR, Hill NS, Horn EM, Leopold JA, Rosenzweig EB, Tang WHW, Wilcox JD. Circ Heart Fail. 2023 Oct;16(10):e010555. doi: 10.1161/CIRCHEARTFAILURE.123.010555. Epub 2023 Sep 4. PMID: 37664964.
Luo Y, Gordon JK, Xu J, Kolstad KD, Chung L, Steen VD, Bernstein EJ; PHAROS Investigators. Rheumatology (Oxford). 2024 May 2;63(5):1251-1258. doi: 10.1093/rheumatology/kead368. PMID: 37478347.
Naranjo M, Rosenzweig EB, Hemnes AR, Jacob M, Desai A, Hill NS, Larive AB, Finet JE, Leopold J, Horn E, Frantz R, Rischard F, Erzurum S, Beck G, Mathai SC, Hassoun PM; PVDOMICS Study Group. Pulm Circ. 2023 Aug 21;13(3):e12281. doi: 10.1002/pul2.12281. eCollection 2023 Jul. PMID: 37614830
Iron deficiency in pulmonary vascular disease: pathophysiological and clinical implications.
Martens P, Yu S, Larive B, Borlaug BA, Erzurum SC, Farha S, Finet JE, Grunig G, Hemnes AR, Hill NS, Horn EM, Jacob M, Kwon DH, Park MM, Rischard FP, Rosenzweig EB, Wilcox JD, Tang WHW; PVDOMICS Study Group. Eur Heart J. 2023 Jun 9;44(22):1979-1991. doi: 10.1093/eurheartj/ehad149. PMID: 36879444.
Pulmonary artery compliance in different forms of pulmonary hypertension.
McCormick A, Krishnan A, Badesch D, Benza RL, Bull TM, De Marco T, Feldman J, Hemnes AR, Hirsch R, Horn E, Kennedy J, Mathai SC, McConnell W, Pugliese SC, Sager JS, Shlobin OA, Simon MA, Lammi MR. Heart. 2023 Jun 26;109(14):1098-1105. doi: 10.1136/heartjnl-2022-321760. PMID: 36787969.
Johannesen J, Fukuda R, Zhang DT, Tak K, Meier R, Agoglia H, Horn E, Devereux RB, Weinsaft JW, Kim J. Echo Res Pract. 2022 Nov 1;9(1):11. doi: 10.1186/s44156-022-00011-8. PMID: 36316750.
Hemnes AR, Leopold JA, Radeva MK, Beck GJ, Abidov A, Aldred MA, Barnard J, Rosenzweig EB, Borlaug BA, Chung WK, Comhair SAA, Desai AA, Dubrock HM, Erzurum SC, Finet JE, Frantz RP, Garcia JGN, Geraci MW, Gray MP, Grunig G, Hassoun PM, Highland KB, Hill NS, Hu B, Kwon DH, Jacob MS, Jellis CL, Larive AB, Lempel JK, Maron BA, Mathai SC, McCarthy K, Mehra R, Nawabit R, Newman JH, Olman MA, Park MM, Ramos JA, Renapurkar RD, Rischard FP, Sherer SG, Tang WHW, Thomas JD, Vanderpool RR, Waxman AB, Wilcox JD, Yuan JX, Horn EM; PVDOMICS Study Group. J Am Coll Cardiol. 2022 Aug 16;80(7):697-718. doi: 10.1016/j.jacc.2022.05.038. PMID: 35953136.
